Global Market Comments
April 2, 2019
Fiat Lux
Featured Trade:
(WHAT’S REALLY BEHIND THE BRISTOL MYERS/CELGENE MERGER),
(BMY), (CELG),
(ON EXECUTING MY TRADE ALERTS),
Global Market Comments
April 1, 2019
Fiat Lux
Featured Trade:
(MARKET OUTLOOK FOR THE WEEK AHEAD, OR THE INMATES ARE RUNNING THE ASYLUM)
(SPY), (TLT), (FCX), (DIS), (TSLA), (IWM), (AAPL),
(GOOGL), (MSFT), (PYPL), (AMZN)
Global Market Comments
March 29, 2019
Fiat Lux
SPECIAL FANG ISSUE
Featured Trade:
(FINDING A NEW FANG),
(FB), (AAPL), (NFLX), (GOOGL),
(TSLA), (BABA)
Global Market Comments
March 28, 2019
Fiat Lux
Featured Trade:
(JOIN US AT THE MAD HEDGE LAKE TAHOE, NEVADA, CONFERENCE, OCTOBER 25-26, 2019)
(THE REBIRTH OF THE MASTER LIMITED PARTNERSHIP),
(USO), (AMLP), (FPL), (MLPS), (MLPX)
Global Market Comments
March 27, 2019
Fiat Lux
Featured Trade:
(JUMP ON THE VERTEX BANDWAGON),
(VRTX), (CRSP),
(MAD HEDGE FUND TRADER CELEBRATES ITS 11-YEAR ANNIVERSARY)
The biotech industry has at least 500 stocks listed on the market today. These companies range from huge biotech firms with several blockbuster drugs to humble money-losing startups still on the lookout for their first big break.
Among these companies, Vertex Pharmaceuticals Incorporated (VRTX) presents a compelling case that could attract investors.
Recent developments on Vertex's triple-combination treatment for cystic fibrosis (CF) have been predicted to spur the company's revenues this year in a major way. If the results of the studies turn out successful, then Vertex is on the verge of becoming the sole treatment provider to at least 90% of the people suffering from this severe genetic condition. That’s a nice monopoly to have.
While the recent developments have yet to aggressively show its effect in Vertex stock, the company has already recorded an impressive 160% growth since 2017 and this is anticipated to go higher in the years to come.
At present, the annual revenue of Vertex is recorded as $3 billion, while major competitors like Pfizer has $53.4 billion, Bristol-Myers Squibb has $22.6 billion, and Novartis has $51 billion. In order words, there is plenty of room to grow.
Just how far can Vertex shares go?
Let's take a look at previous reports on the company. Its December 2018 financial report reveals that its earnings per share jumped by 113% year-over-year to $1.3. Its quarterly revenues increased by 40% and reached $869.44 million -- a gigantic 39.7% leap from the $622.63 million it achieved during the same period in the previous year.
While the March 2019 EPS for this company is anticipated to go down to $0.68 compared to the $0.76 recorded the same period last year, its 2020 EPS is projected to get a 49.46% boost. With that estimate, Vertex is expected to reach its long-term annual earnings growth rate of 53.86%.
How can investors be sure that Vertex continues with its remarkable progress?
The company's moves in the past months have been quite promising. A major factor that could guarantee its success is its dominance in the CF market. At the moment, Vertex has three approved CF drugs available in the market: Kalydeco, Orkambi, and Symdeko.
Of these three, two are already considered as blockbuster products while Symdeko is poised to hit the $1 billion yearly sales mark this year.
Another promising reason to invest in Vertex is its move to expand the addressable CF market it currently covers. If the company succeeds in cornering the market for treating younger patients, then its target population will increase from 39,000 to 44,000.
Vertex is also working towards gaining approval for a triple-drug combo this year. The biotech company projects an additional 24,000 patients globally to benefit from this triple-drug regimen.
Should all these plans fall into place, Vertex would see a 75% expansion on its addressable CF market in the years to come.
Although CF has been the focus of Vertex in the previous years, the company also intends to widen its scope and plans to conduct early-stage clinical studies for at least two new diseases this year.
This move would prove to be beneficial in the long-term considering the decision of AbbVie Inc (ABBV) to join the triple-drug CF race. So far, AbbVie has a long way to go before it can catch up with Vertex's progress in this arena especially since the latter practically has a monopoly as it alone offers the drugs that can treat the underlying causes of CF.
Vertex's collaboration with CRISPR Therapeutics (CRSP) on gene-editing treatments, which aim to treat rare blood disorders beta-thalassemia and sickle cell disease, is yet another promising development for the company.
All in all, Vertex is a good biotech stock to invest in today. However, its plans are not foolproof.
There remains the risk that its pipeline candidates fail at clinical trials or that the company loses its bids for regulatory approvals. Nonetheless, it's a promising stock to add to your portfolio especially since the company has more than doubled its stock in the past two years.
High risk, high gain. Welcome to the world of biotech stocks.
The Diary of a Mad Hedge Fund Trader is now celebrating its 11th year of publication.
During this time, I have religiously pumped out 1,500 words a day, or eight double-spaced typed pages, of original, independent-minded, hard-hitting, and often wickedly funny research.
I’ve been covering stocks, bonds, commodities, energy, precious metals, real estate, and agricultural products.
You’ve been kept up on my travels around the world and listened in on my conversations with those who drive the financial markets.
I also occasionally opine on politics, but only when it has a direct market impact, such as with the recent administration's economic and trade policies.
The site now contains over 11 million words or 13 times the length of Tolstoy’s epic War and Peace.
Unfortunately, it feels like I have written on every possible topic at least 100 times over.
So, I am reaching out to you, the reader, to suggest new areas of research that I may have missed until now which you believe justify further investigation.
Please send any and all ideas directly to me at support@madhedgefundtrader.com/, and put “RESEARCH IDEA” in the subject line.
The great thing about running an online business is that I can evolve it to meet your needs on a daily basis.
Many of the new products and services that I have introduced since 2008 have come at your suggestion. That has enabled me to improve the product’s quality to your benefit.
This originally started out as a daily email to my hedge fund investors giving them an update on fast market-moving events. That was at a time when the financial markets were in free fall and the end of the world seemed near.
Here’s a good trading rule of thumb: Usually, the world doesn’t end. History doesn’t repeat itself, but it certainly rhymes.
The daily emails gave me the scalability that I so desperately needed. Today’s global mega enterprise grew from there. Today, the Diary of a Mad Hedge Fund Trader and its Global Trading Dispatch is read in over 140 countries by 24,000 followers.
I’m weak in North Korea and Mali, in both cases due to the lack of electricity. But that may change.
If you want to read my first pitiful attempt at a post, please click here for my February 1, 2008 post.
It urged readers to buy gold at $950 (it soared to $1,920), and buy the Euro at $1.50 (it went to $1.60).
Now you know why this letter has become so outrageously popular.
Unfortunately, I also recommended that they sell bonds short. I wasn’t wrong on that one, just early, about eight years too early.
I always get asked how long will I keep doing this?
The government tells me that the latest I can start drawing down on my retirement funds and Social Security is 70. That’s some three years off for me.
Given the absolute blast I have doing this job, that is highly unlikely. Take a look at the testimonials I get only an almost daily basis and you’ll see why this business is so hard to walk away from (click here for those).
In the end, you are going to have to pry my cold dead fingers off of this keyboard to get me to give up.
Fiat Lux (let there be light).
Global Market Comments
March 26, 2019
Fiat Lux
Featured Trade:
(WHY I’M SELLING SHORT TESLA SHARES),
(TSLA)
The news is out that new Tesla (TSLA) new car registrations in the major states are falling off a cliff. California, New York, and even Texas are the major culprits.
The company says the ramp up in mass production of the Tesla 3 is the main reason, and that car registrations, in any case, are a deep lagging indicator. (No kidding! I bought a Model X P100D in Nevada in November and it is still not registered).
Analysts say it is because the electric car subsidy was chopped in half by the Trump administration this year from $7,500 to $3,750 per vehicle, and it is going to zero next year, thus demolishing the Tesla 3 market for entry-level low-end buyers. They also point to the company’s fragile financial condition which could be going bankrupt at any time.
For whatever reason, I believe that the shares will break two-year support on the charts and plunge to new lows. At the very least, Tesla shares are capped for the time being.
I, therefore, sold short Tesla shares yesterday.
As much as this looks like a great short-term trade, I love Tesla long term and see it as a potential ten bagger from current price levels. Tesla will become the world’s largest car company within a decade and become the first car company with a $1 trillion market valuation.
As long as I have been following Tesla since the early venture capital days, it has been going bankrupt. It was going bankrupt during the move in the share price from $16.50 to $394, and it is going bankrupt today.
When I pulled up to the Fremont factory last week, I couldn’t believe what I found. There was a version 3 supercharger that would top up my battery at the staggering rate of 1,000 miles an hour!
That meant that with 50 miles of range left on my 300-mile range Model X battery, I could get a full charge in 15 minutes! The electric power was coming down the cable so fast that it had to be liquid-cooled.
I pinched myself to make sure I hadn’t fallen into a Star Trek movie. The V3 supercharger will soon be available across the country. No other car company is close to achieving something like this.
The fact is that I have been subjected to an unrelenting torrent of bad news, rumors, and envy since I first bought the shares at $16.50 ten years ago. This is the most despised company in the universe and regularly sits among the top five companies with the greatest short interest, often above 25%.
But I guess this is what happens when you take on big oil, the Detroit big three, the advertising industry, labor unions, and the entire Republican party all at once. By my calculation, Tesla is a disruptive threat to about 50% of the US GDP all at once.
I ignore them all and just look at the numbers. Here they are.
1) Tesla has increased its total production from 125 when I bought my first Model S1 in 2009 to 245,519 in 2018. It should hit 500,000 by the end of this year when the Shanghai factory comes online. They have gone from employing 100 people to 50,000.
2) With the completion of the Sparks, NV Gigafactory, battery prices are collapsing and are now 50% cheaper per mile than any other competitor, 4.1 miles per kWh versus 2.5 miles.
3) Tesla’s costs for batteries have cratered from $1,000 per kWh ten years ago to $100 per kWh today and are expected to drop to $75 per kWh in a few years. Below $100 per kWh Teslas are cheaper to run than conventional gasoline-powered cars, even without the tax subsidy.
4) Tesla now makes half the lithium batteries in the world, and that figure is growing by 50% a year.
5) Tesla’s vast national charger network will soon become the country’s largest electric power utility and that will also become an enormous money-spinner. They just raised prices to 30 cents per kWh versus a cost of 5 cents. Assuming that 5 million cars buy a 70-kWh charge three times a week, that works out to a $13.65 billion a year profit.
6) Anyone who actually reads Tesla’s balance sheet can see that the company is now spinning off $1 billion in free cash flow. It is investing in new plant and equipment at a prodigious rate.
7) With a market capitalization of $44.5 billion, Tesla just trails General Motors (GM) at $51 billion, but surpasses Ford Motors at $34 billion, and therefore can raise new capital to finance its hyper-growth any time it wants.
More product at high prices at a prodigiously falling cost sounds like a pretty good business model to me. Oh, and climate change is about to become the top political issue for the 2020 presidential election. Who is the big winner in that case?
Tesla.
Global Market Comments
March 25, 2019
Fiat Lux
Featured Trade:
(MARKET OUTLOOK FOR THE WEEK AHEAD, OR GAME CHANGER)
(SPY), (TLT), (BIIB), (GOOG), (BA), (AAPL), (VIX), (USO)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.